
Switching between ranibizumab and aflibercept for the treatment of neovascular age-related macular degeneration
Keywords: محصولات دیرگداز، دیرگداز; age-related macular degeneration; vascular endothelial growth factor; ranibizumab; lucentis; aflibercept; eylea; switch; refractory;